Somewhat to our surprise, Mayo Clinic abruptly cancelled my participation in the study at the visit which ended my 89th 28-day cycle. As far as I know the drug manufacturer, Celgene, was prepared to continue the study, but Mayo explained that they needed the resources elsewhere.
I headed home from that last visit with no meds and wondering how or when I would get them, and also wondering if or when I would have any appointment. Happily, answers to those questions came in a few days (after some phone calls) and treatment is back on track. My copay is quite manageable, and of course I'm aware that there are organizations that will help with the copay if I seek help.
I've now had my first "regular" appointment at Mayo, where we established a new schedule: I will continue to get myeloma markers checked every month, but will actually drive the 200-mile round trip to Mayo only every second or third month, otherwise mailing in the blood samples and getting the results online. The next Mayo visit will be in April and we will do either an x-ray bone survey or a PET scan at that time, to be determined after this upcoming marathon.
This time Mayo chose to do my CBC in the morning, together with all of the other blood tests, and found that the neutrophil count was barely above the lower limit of 1.0 k/uL. We decided to go back to our earlier practice of taking the CBC the afternoon before the visit, because the afternoon neutrophil count is usually double the morning reading. The neutrophils are there in the morning too of course - they apparently just don't like to get up early. There may be a better medical explanation for that.
Results from the last study cycle and this first regular cycle indicate that the myeloma is still stable, with an IgG of 1270 mg/dL and M-Spike of 1200 mg/dL (1.2 g/dL). Both of these values are within the range of values seen recently. The myeloma will probably take over someday, but not yet.
|At a gluten-free restaurant called Nourish in Gilbert, AZ.|
That dressing is lime-based, perfect for the salmon and the salad.